Symbols

SDGR

Schrodinger·NASDAQ

--(--)

SDGR fundamentals

SDGR Q4 2025 Earnings

Schrodinger (SDGR) released its earnings on Feb 25, 2026: revenue was 87.20M (YoY -1.25%), beat estimates; EPS was 0.45 (YoY +181.82%), beat estimates.

Revenue / YoY

87.20M

-1.25%

EPS / YoY

0.45

+181.82%

Report date

Feb 25, 2026

SDGR Earnings Call Summary for Q4,2025

2025 Growth: 23% total revenue growth, $198.5 million software ACV, 15% top 20 pharma growth, and 7% commercial expansion.
Hosted Transition: 23% hosted revenue in 2025, targeting 75% by 2028 for predictable financials. 2026 ACV guidance $218-228 million (+10-15%).
AI & New Products: Predictive tox beta success; 2026 launches to drive growth in biologics, toxicology, and materials science.
Therapeutics Momentum: 25 active programs, 7 in clinical trials, and $56 million 2025 drug discovery revenue. 2028 target: $50 million annual drug discovery revenue.
2028 Financial Goals: Positive adjusted EBITDA, 75% hosted revenue, and high 70s gross margin.

Earnings

EPS

Revenue

Revenue & Expenses

SDGR has released its 2025 Q4 earnings report, with revenue of 87.23M, reflecting a YoY change of -1.23%, and net profit of 32.51M, showing a YoY change of 180.84%. The Sankey diagram below clearly presents SDGR's revenue sources and cost distribution.

Key Indicators

Schrodinger (SDGR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Schrodinger (SDGR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Schrodinger (SDGR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Schrodinger (SDGR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown